JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.63B |
| 2 |
JPMorgan BetaBuilders Japan ETF
BBJP
|
+$1.83B |
| 3 |
JPMorgan BetaBuilders International Equity ETF
BBIN
|
+$1.55B |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$1B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$884M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI EAFE ETF
IEFA
|
+$1.8B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$1.77B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$884M |
| 4 |
iShares Core US Aggregate Bond ETF
AGG
|
+$880M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$834M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.09% |
| 2 | Technology | 16.19% |
| 3 | Financials | 10.76% |
| 4 | Healthcare | 10.54% |
| 5 | Consumer Discretionary | 10.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3826
Designer Brands
DBI
$305M
| $357K | ﹤0.01% |
52,774
+18,334
| +53% | +$111K |
2015 Q1
21 quarters
|
|
3827
Korro Bio
KRRO
$147M
| $356K | ﹤0.01% |
307
+115
| +60% | +$104K |
2019 Q4
2 quarters
|
|
|
TUP
3828
DELISTED
Tupperware Brands Corporation
TUP
| $356K | ﹤0.01% |
75,039
-231,163
| -75% | -$769K |
2013 Q2
28 quarters
|
|
|
LTHM
3829
DELISTED
Livent Corporation
LTHM
| $356K | ﹤0.01% |
57,842
-9,345
| -14% | -$58.9K |
2018 Q4
6 quarters
|
|
3830
Harrow
HROW
$1.15B
| $355K | ﹤0.01% |
68,162
+9,914
| +17% | +$48.7K |
2019 Q3
3 quarters
|
|
3831
Bain Capital Specialty
BCSF
$707M
| $354K | ﹤0.01% |
31,961
+28,450
| +810% | +$294K |
2019 Q2
4 quarters
|
|
3832
e.l.f. Beauty
ELF
$6.12B
| $354K | ﹤0.01% |
18,560
-564
| -3% | -$8.07K |
2016 Q3
15 quarters
|
|
3833
Viridian Therapeutics
VRDN
$2.15B
| $354K | ﹤0.01% |
21,290
| – | – |
2017 Q3
11 quarters
|
|
|
IBDP
3834
DELISTED
iShares iBonds Dec 2024 Term Corporate ETF
IBDP
| $354K | ﹤0.01% |
13,444
+9,813
| +270% | +$253K |
2019 Q4
2 quarters
|
|
|
STND
3835
DELISTED
Standard AVB Financial Corp. Common Stock
STND
| $354K | ﹤0.01% |
+15,254
| New | +$355K |
2020 Q2
0 quarters
|
|
3836
WisdomTree US High Dividend Fund
DHS
$1.55B
| $353K | ﹤0.01% |
5,663
-4,211
| -43% | -$259K |
2013 Q2
28 quarters
|
|
|
CBIO
3837
Crescent Biopharma
CBIO
$518M
| $353K | ﹤0.01% |
938
+627
| +202% | +$178K |
2018 Q2
8 quarters
|
|
3838
CB Financial Services
CBFV
$188M
| $352K | ﹤0.01% |
+16,135
| New | +$360K |
2020 Q2
0 quarters
|
|
|
MTL
3839
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
| $352K | ﹤0.01% |
204,457
-242,686
| -54% | -$425K |
2015 Q4
18 quarters
|
|
3840
Navios Maritime Partners
NMM
$2.68B
| $350K | ﹤0.01% |
36,005
-152,958
| -81% | -$1.1M |
2013 Q2
28 quarters
|
|
3841
Tactile Systems Technology
TCMD
$509M
| $350K | ﹤0.01% |
8,435
-26,425
| -76% | -$1.24M |
2017 Q4
10 quarters
|
|
|
IHC
3842
DELISTED
Independence Holding Company
IHC
| $350K | ﹤0.01% |
11,415
-5,704
| -33% | -$159K |
2017 Q4
10 quarters
|
|
|
ATAXZ
3843
DELISTED
AMERICA FIRST TAX EXEMT INV LP
ATAXZ
| $350K | ﹤0.01% |
84,978
+24,500
| +41% | +$101K |
2015 Q1
21 quarters
|
|
3844
CALL
Allstate
ALL
$56.8B
| $349K | ﹤0.01% |
3,600
-586,600
| -99% | -$57.6M |
2018 Q4
6 quarters
|
|
3845
Simulations Plus
SLP
$374M
| $349K | ﹤0.01% |
5,833
+1,913
| +49% | +$84.2K |
2017 Q4
10 quarters
|
|
|
CPAC
3846
Cementos Pacasmayo
CPAC
$1.05B
| $347K | ﹤0.01% |
39,877
| – | – |
2018 Q3
7 quarters
|
|
|
STEL
3847
DELISTED
Stellar Bancorp
STEL
| $347K | ﹤0.01% |
16,499
-32,167
| -66% | -$595K |
2017 Q4
10 quarters
|
|
3848
Bally's
BALY
$696M
| $344K | ﹤0.01% |
15,426
-179,172
| -92% | -$3.16M |
2019 Q2
4 quarters
|
|
|
NFH
3849
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
| $344K | ﹤0.01% |
+41,519
| New | +$337K |
2020 Q2
0 quarters
|
|
3850
United Microelectronic
UMC
$60B
| $343K | ﹤0.01% |
+130,001
| New | +$327K |
2020 Q2
0 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2020 Portfolio in Review
As of Q2 2020, JP Morgan Chase held 5,976 positions worth $518B, up 22% from $426B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q2 2020 filing shows 640 new, 2,055 increased, 2,340 reduced and 398 closed positions. Its largest new stake was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B. The largest sale was iShares Core MSCI EAFE ETF, an estimated $1.8B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 28% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2020 buy was JPMorgan BetaBuilders International Equity ETF: 35,626,738 shares worth $1.64B.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q2 2020, an estimated $2.63B increase.
- JP Morgan Chase's biggest Q2 2020 reduction was iShares Core MSCI EAFE ETF, cutting an estimated $1.8B.
- JP Morgan Chase fully exited Allergan plc in Q2 2020, selling an estimated $656M.
- JP Morgan Chase's ten largest holdings make up 17% of its $518B portfolio in Q2 2020.
- JP Morgan Chase opened 640 new positions and closed 398 in Q2 2020.
- JP Morgan Chase's portfolio value rose 22% quarter-over-quarter to $518B.
Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.